Risk factors for recurrence and severity of an ulcerative colitis attack

DOI: https://doi.org/10.29296/25877305-2022-05-08
Issue: 
5
Year: 
2022

Professor E. Bolotova(1), MD; K. Yumukyan(1, 2); A. Dudnikova(1), Candidate of Medical Sciences; M. Yakovenko(2), Candidate of Medical Sciences
1-Kuban State Medical University, Ministry of Health of Russia, Krasnodar
2-Research Institute – S.V. Ochapovsky Territorial Clinical Hospital One, Krasnodar

Objective. To analyze risk factors for recurrence and severity of an ulcerative colitis (UC) attack. Material and methods. A retrospective study that included 315 medical records of UC patients (167 and 148 inpatient and outpatient records, respectively) was conducted. Results. Patients with recurrent UC requiring hospitalization were observe to have statistically significantly increases in the duration of the disease, in the frequency of exacerbations/exacerbations in their history and the frequency of using biological agents, a younger age at the onset of UC, a low status of current smoking and ex-smoking as compared with those in patients in remission. Severe UC was associated with the following factors: a young age at the onset of UC; a lower body mass index, a history of biological therapy; a positive fecal occult blood test at the time of hospitalization; lower hemoglobin and albumin levels; higher erythrocyte sedimentation rate and C-reactive protein; a large extent of intestinal damage; and deep ulcerative defects in the colon mucosa. Conclusion. Analysis of risk factors for recurrence and severity of an UC attack aids in the personalization of treatment, in the prediction of therapeutic response, in the evaluation of the likelihood of adverse effects, and in the optimization of the early diagnosis of the risk of relapse in UC and its severe attack.
Keywords: 
gastroenterology; risk of recurrence in ulcerative colitis; severity of ulcerative colitis attack; risk factors
endocrinology
type 2 diabetes mellitus
coronavirus infection
metformin
diabetes mellitus treatment
insulin therapy
chronic diseases

References: 
  1. Holvoet T., Lobaton T., Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol. 2021; 14: 71–81. DOI: 10.2147/CEG.S197719
  2. Gallo G., Kotze P.G., Spinelli A. Surgery in ulcerative colitis: When? How? Best Pract Res Clin Gastroenterol. 2018; 32–33: 71–8. DOI: 10.1016/j.bpg.2018.05.017
  3. Tertychny A.S., Akhrieva Kh.M., Maev I.V. et al. Diagnostic problems of histological remission in patients with inflammatory bowel disease. Arkhiv Patologii. 2017; 79 (3): 3–9 (in Russ.). DOI: 10.17116/patol20177933-9
  4. Ivashkin V.T., Shelygin Yu.A., Abdulganiyeva D.I. et al. Guidelines of the Russian gastroenterological association and Russian Association of Coloproctology on diagnostics and treatment of ulcerative colitis in adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015; 25 (1): 48–65 (in Russ.).
  5. Frolkis A.D., Dykeman J., Negrón M.E. et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013; 145 (5): 996–1006. DOI: 10.1053/j.gastro.2013.07.041
  6. Lamb C.A., Kennedy N.A., Raine T. et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults [published correction appears in Gut. 2021; 70 (4): 1]. Gut. 2019; 68 (3): s1-s106. DOI: 10.1136/gutjnl-2019-318484
  7. Mathurin F. et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018; 16 (3): 343-356.e3. DOI: 10.1016/j.cgh.2017.06.016
  8. Bopanna S., Ananthakrishnan A.N., Kedia S. et al. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017; 2 (4): 269–76. DOI: 10.1016/S2468-1253(17)30004-3
  9. Kotze P.G., Steinwurz F., Francisconi C. et al. Review of the epidemiology and burden of ulcerative colitis in Latin America. Ther Adv Gastroenterol. 2020; 13: 1756284820931739. DOI: 10.1177/1756284820931739
  10. Bikbavova G.R., Livzan M.A., Novikov D.G. et al. Precision medicine and inflammatory bowel diseases: concept, strategies, future. Experimental and Clinical Gastroenterology. 2021; 1 (6): 121–9 (in Rus.). DOI: 10.31146/1682-8658-ecg-190-6-121-129
  11. Kucharzik T., Koletzko S., Kannengiesser K. et al. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms. Dtsch Arztebl Int. 2020; 117 (33–34): 564–74. DOI: 10.3238/arztebl.2020.0564
  12. Oh S.J., Shin G.Y., Soh H. et al. Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis. Intest Res. 2021; 19 (3): 323–31. DOI: 10.5217/ir.2020.00039
  13. Lau A., Chande N., Ponich T. et al. Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2008; 28 (5): 606–13. DOI: 10.1111/j.1365-2036.2008.03772.x
  14. Tanaka M., Takagi T., Naito Y. et al. Low serum albumin at admission is a predictor of early colectomy in patients with moderate to severe ulcerative colitis. JGH Open. 2021; 5 (3): 377–81. DOI: 10.1002/jgh3.12506
  15. Wagatsuma K., Yokoyama Y., Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel). 2021; 11 (12): 1375. DOI: 10.3390/life11121375
  16. Kato J., Yoshida T., Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol. 2019; 15 (6): 667–77. DOI: 10.1080/1744666X.2019.1593140
  17. Burisch J., Ungaro R., Vind I. et al. Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort. J Crohns Colitis. 2017; 11 (10): 1200–4. DOI: 10.1093/ecco-jcc/jjx066
  18. Chen Y., Gong X., Wang L. et al. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis. medRxiv. 2020.; 14 (4): 303–10. DOI: 10.1101/2020.03.25.20043133
  19. Chen T., Wu D., Chen H. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368: m1091. DOI: 10.1136/bmj.m1295
  20. Wu Z., McGoogan J.M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323 (13): 1239–42. DOI: 10.1001/jama.2020.2648
  21. Cameron A.R., Morrison V.L., Levin D. et al. Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status. Circ Res. 2016; 119 (5): 652–65. DOI: 10.1161/CIRCRESAHA.116.308445
  22. Crouse A.B., Grimes T., Li P. et al. Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes. Front Endocrinol. 2020; 11: 600439. DOI: 10.3389/fendo.2020.600439
  23. Drucker D.J. Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications. Endocr Rev. 2020; 41 (3): bnaa011. DOI: 10.1210/endrev/bnaa011
  24. Samuel S.M., Ghosh S., Majeed Y. et al. Metformin represses glucose starvation induced autophagic response in microvascular endothelial cells and promotes cell death. Biochem Pharmacol. 2017; 132: 118–32. DOI: 10.1016/j.bcp.2017.03.001
  25. Triggle C.R., Ding H. Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium. Acta Physiol (Oxf). 2017; 219 (1): 138–51. DOI: 10.1111/apha.12644
  26. Samuel S.M., Varghese E., Kubatka P. et al. Metformin: The Answer to Cancer in a Flower? Current Knowledge and Future Prospects of Metformin as an Anti-Cancer Agent in Breast Cancer. Biomolecules. 2019; 9 (12): 846. DOI: 10.3390/biom9120846
  27. Varghese S., Samuel S.M., Varghese E. et al.. High Glucose Represses the Anti-Proliferative and Pro-Apoptotic Effect of Metformin in Triple Negative Breast Cancer Cells. Biomolecules. 2019; 9 (1): 16. DOI: 10.3390/biom9010016
  28. Samuel S.M., Varghese E., Büsselberg D. Therapeutic Potential of Metformin in COVID-19: Reasoning for its Protective Role. Trends Microbiol. 2021; 29 (10): 894–907. DOI: 10.1016/j.tim.2021.03.004
  29. Allard R., Leclerc P., Tremblay C. et al. Diabetes and the severity of pandemic influenza A (H1N1) infection. Diabetes Care. 2010; 33 (7): 1491–3. DOI: 10.2337/dc09-2215
  30. Kulcsar K.A., Coleman C.M., Beck S.E. et al. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight. 2019; 4 (20): e131774. DOI: 10.1172/jci.insight.131774
  31. Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020; 39: 101044. DOI: 10.1016/j.molmet.2020.101044
  32. Zhu L., She Z.G., Cheng X. et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020; 31 (6): 1068–77.e3. DOI: 10.1016/j.cmet.2020.04.021
  33. Lisco G., De Tullio A., Giagulli V.A. et al. Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: a review. Endocrine. 2020; 70 (3): 441–53. DOI: 10.1007/s12020-020-02444-9
  34. Teuwen L.A., Geldhof V., Pasut A. et al. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020; 20 (7): 389–91. DOI: 10.1038/s41577-020-0343-0
  35. Sun Q., Li J., Gao F. New insights into insulin: The anti-inflammatory effect and its clinical relevance. World J Diabetes. 2014; 5 (2): 89–96. DOI: 10.4239/wjd.v5.i2.89
  36. Sardu C., D’Onofrio N., Balestrieri M.L. et al. Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care. 2020; 43 (7): 1408–15. DOI: 10.2337/dc20-0723
  37. Sharma S., Ray A., Sadasivam B. Metformin in COVID-19: A possible role beyond diabetes. Diabetes Res Clin Pract. 2020; 164: 108183. DOI: 10.1016/j.diabres.2020.108183
  38. Bramante C.T., Buse J., Tamaritz L. et al. Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. J Med Virol. 2021; 93 (7): 4273–9. DOI: 10.1002/jmv.26873
  39. Hariyanto T.I., Kurniawan A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection. Obes Med. 2020; 19: 100290. DOI: 10.1016/j.obmed.2020.100290
  40. Lalau J.D., Al-Salameh A., Hadjadj S. et al. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab. 2020; 47 (5): 101216. DOI: 10.1016/j.diabet.2020.101216
  41. Giannarelli R., Aragona M., Coppelli A. et al. Reducing insulin resistance with metformin: the evidence today. Diabetes Metab. 2003; 29 (4, Part 2): 6S28–6S35. DOI: 10.1016/s1262-3636(03)72785-2
  42. Lim S., Bae J.H., Kwon H.S. et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021; 17 (1): 11–30. DOI: 10.1038/s41574-020-00435-4
  43. Zimmet P., Collier G. Clinical Efficacy of Metformin against Insulin Resistance Parameters. Drugs. 1999; 58 (1): 21–8. DOI: 10.2165/00003495-199958001-00007
  44. Bramante C.T., Ingraham N.E., Murray T.A. et al. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev. 2021; 2 (1): e34–e41. DOI: 10.1016/S2666-7568(20)30033-7
  45. Tsai S., Clemente-Casares X., Zhou A.C. et al. Insulin Receptor-Mediated Stimulation Boosts T Cell Immunity during Inflammation and Infection. Cell Metab. 2018; 28 (6): 922–34.e4. DOI: 10.1016/j.cmet.2018.08.003
  46. ClinicalTrials.gov. Adaptive Study to Demonstrate Efficacy and Safety of Metformin Glycinate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2. Randomized, Double-Blind, Phase IIIb. 2021 [cited 2021 Feb 10]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04625985?term=metformin&cond=COVID&draw=2&rank=3
  47. Dedov D. Novel coronavirus infection (COVID-19): epidemiology, clinical characteristics of patients, risk of complications, prevention, use of selenium-containing drugs. Vrach. 2022; 33 (5); 58–62 (in Russ.). DOI: 10.29296/25877305-2022-05-12